Inhibition of BRD4 and mTOR pathway can modulate HVEM and GAL-9 in AML cells
DOI:
https://doi.org/10.11606/issn.1679-9836.v102iespe-204653Palavras-chave:
AML, JQ1, Rapamycin, HVEM, GAL-9, BRD4 protein, Acute Myeloid LeukemiaDownloads
Referências
Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia. Blood. 2016;127(1):53-62. doi: https://doi.org/10.1182/blood-2015-08-604520
Khwaja A, Bjorkholm M, Gale RE, Levine RL, Jordan CT, Ehninger G, et al. Acute myeloid leukaemia. Nat Rev Dis Prim. 2016;2 2:16010. doi: https://doi.org/10.1038/nrdp.2016.10
Rathert P, Roth M, Neumann T, Muerdter F, Roe JS, Muhar M, et al. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature. 2015;525(7570):543-7. doi: https://doi.org/10.1038/nature14898.
Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011;478(7370):524-8. doi: https://doi.org/10.1038/nature10334
Altman JK, Sassano A, Platanias LC. Targeting mTOR for the treatment of AML . new directions. New agents and Abstract : TORC1 mTOR TORC2 mTOR. Oncotarget. 2011;2(6):510-7. doi: https://doi.org/10.18632/oncotarget.290
Pal D, Vann KR, Joshi S, Sahar NE, Morales GA, El-Gamal D, et al. The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma. iScience. 2021;24(9):102931. https://doi.org/10.1016/j.isci.2021.102931
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2023 Ana Carolina Costanti Nascimento, Elayne Bragança-Jardim, Letícia Borges da Silva Heinen , Vanessa Araújo Varela, Welbert de Oliveira Pereira, Mariane Tami Amano
Este trabalho está licenciado sob uma licença Creative Commons Attribution-ShareAlike 4.0 International License.